EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Safety and Efficacy of the Passeo-18 Lux Drug-Coated Balloon Catheter in Atherosclerotic Femoropopliteal Lesions: The Multicenter BIOLUX P-IV China Study

Jue Yang, Jianing Yue, Xueming Chen, Haofu Wang, Weiliang Jiang, Xiaojin Huang, Xinwu Lu, Honglin Dong, Xuan Li, Weiguo Fu

Annals of Vascular Surgery · 2023

DOI: 10.1016/j.avsg.2023.01.040 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Vascular Surgery, 2023. Verfasst von Jue Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Surgery, Zhongshan Hospital of Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Peripheral Arterial Disease, Atherosclerosis, Angioplasty, Balloon. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The purpose of this trial was to assess the safety and effectiveness of a paclitaxel-coated balloon catheter in Chinese patients with de novo or nonstented restenotic femoropopliteal atherosclerotic lesions. METHODS: BIOLUX P-IV China is a prospective, independently adjudicated, multicenter, single-arm trial conducted in China. Patients with Rutherford class 2-4 were eligible, excluded were patients in which predilation resulted in severe (≥ grade D) flow-limiting dissection or residual stenosis > 70%. Follow-up assessments were conducted at 1, 6, and 12 months. The primary safety end point was 30-day major adverse event rate and the primary effectiveness end point was primary patency at 12 months. RESULTS: We enrolled 158 patients with 158 lesions. Mean age was 67.6 ± 9.6 years, diabetes was present in 53.8% (n = 85), and previous peripheral intervention/surgeries in 17.1% (n = 27). Lesions were 4.1 ± 0.9 mm in diameter and 74 ± 50 mm long with a mean diameter stenosis of 91 ± 13%; 58.2% (n = 92) were occluded (core laboratory analysis). Device success was achieved in all patients. The rate of major adverse events was 0.6% (95% confidence interval: 0.0; 3.5) at 30 days, consisting of 1 target lesion revascularization. At 12 months, binary restenosis was present in 18.7% (n = 26) and target lesion revascularization was performed in 1.4% (n = 2, all clinically driven), resulting in a primary patency of 80.0% (95% confidence interval: 72.4, 85.8); no major target limb amputation occurred. Clinical improvement at 12 months, defined as improvement of at least 1 Rutherford class, was 95.3% (n = 130). The median walking distance per 6-minute walk test was 279 m at baseline and improved by 50 m at 30 days and by 60 m at 12 months; the visual analogue scale changed from 76.6 ± 15.6 at baseline to 80.0 ± 15.0 at 30 days and 78.6 ± 14.6 at 12 months. CONCLUSIONS: Our results confirmed the clinical effectiveness and safety of a paclitaxel-coated peripheral balloon dilatation catheter for the treatment of de novo and nonstented restenotic lesion of the superficial femoral and proximal popliteal artery in Chinese patients (NCT02912715).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peripheral Arterial DiseaseAtherosclerosisAngioplasty, BalloonHumansMiddle AgedAgedProspective StudiesConstriction, PathologicTreatment OutcomeLimb SalvageFemoral ArteryPopliteal ArteryPaclitaxelChinaCoated Materials, BiocompatibleCathetersVascular Patency

Substanzen

PaclitaxelCoated Materials, Biocompatible

Autor:innen und Institutionen

  • Department of Vascular Surgery, Zhongshan Hospital of Fudan University, Shanghai, China.
  • Department of Vascular Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
  • Department of Vascular Surgery, Affiliated Hospital of Qingdao University, Qingdao, China.
  • Department of Vascular Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
  • Department of Vascular Surgery, Zhongshan Hospital Xiamen University, Xiamen, China.
  • Department of Vascular Surgery, Shanghai Nineth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Zitieren

APA

Yang, J., Yue, J., Chen, X., Wang, H., Jiang, W., Huang, X., Lu, X., Dong, H., Li, X., & Fu, W. (2023). Safety and Efficacy of the Passeo-18 Lux Drug-Coated Balloon Catheter in Atherosclerotic Femoropopliteal Lesions: The Multicenter BIOLUX P-IV China Study. Annals of Vascular Surgery. https://doi.org/10.1016/j.avsg.2023.01.040

Vancouver

Yang J, Yue J, Chen X, Wang H, Jiang W, Huang X, et al. Safety and Efficacy of the Passeo-18 Lux Drug-Coated Balloon Catheter in Atherosclerotic Femoropopliteal Lesions: The Multicenter BIOLUX P-IV China Study. Annals of Vascular Surgery. 2023. doi:10.1016/j.avsg.2023.01.040

BibTeX
@article{Yang2023,
  author = {Yang, Jue and Yue, Jianing and Chen, Xueming and Wang, Haofu and Jiang, Weiliang and Huang, Xiaojin and Lu, Xinwu and Dong, Honglin and Li, Xuan and Fu, Weiguo},
  title = {Safety and Efficacy of the Passeo-18 Lux Drug-Coated Balloon Catheter in Atherosclerotic Femoropopliteal Lesions: The Multicenter BIOLUX P-IV China Study},
  journal = {Annals of Vascular Surgery},
  year = {2023},
  doi = {10.1016/j.avsg.2023.01.040}
}
Kostenlos starten →